Skip to content
Search our Site
Search our site
Search our site
My PD Journey
About the EPDA
Political affairs and policy
Medical and pharmaceutical
Political and policy
World PD Day News
Resources and publications
European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson´s disease patients with motor fluctuations
BIAL announced today that the medicinal product ONGENTYS (opicapone) for the treatment of adult Parkinson´s disease patients with motor fluctuations was approved by the European Commission. BIAL will make ONGENTYS available for Parkinson's disease patients across Europe in 2016 and 2017.
05 July 2016
EMA and FDA reinforce collaboration on patient engagement
The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have set up a new 'cluster' on patient engagement.
22 June 2016
A new online resource to manage everyday diet for people with Parkinson's disease
The newly launched website www.MyPerfectDish.com is a useful dietary tool for people with Parkinson's, relatives, caregivers and physicians.
21 June 2016
Clint's Parkinson's 100 Challenge - 24 hours non-stop walk - once more!
I am happy to announce I will repeat the challenge I endured in December; this time with my colleague Hannah and warmer weather I hope!
08 June 2016
NTCELL demonstrates continued reversal of Parkinson's disease
81 weeks after treatment all four patients who took part in Living Cell Technologies Limited's Phase I/IIa clinical study of NTCELL for Parkinson's disease show reversal of the progression of Parkinson's disease as measured by globally accepted and validated Unified Parkinson's Disease Rating Scale (UPDRS).
07 June 2016
The Michael J. Fox Foundation for Parkinson's Research joins multinational critical path for Parkinson's Consortium
The Michael J. Fox Foundation for Parkinson's Research (MJFF), with Parkinson's UK and the Critical Path Institute (C-Path) in Tucson, Arizona, announce that MJFF has joined the Critical Path for Parkinson's Consortium (CPP). The consortium aims to create a quantitative model of Parkinson's progression from its earliest stages that will allow researchers to optimize clinical trial design for faster and more effective testing of novel therapies.
18 May 2016
Subscribe to this page >
Back to Top
Add page to PDF basket
Copyright © 2016 EPDA. All Rights Reserved.
Privacy and cookies